Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
about
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose ControlInsulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's diseaseElevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brainTherapeutic targets of brain insulin resistance in sporadic Alzheimer's diseaseBrain insulin resistance and deficiency as therapeutic targets in Alzheimer's diseaseCSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's DiseaseGLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic miceIntranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative DiseasesNeuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway.Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's diseaseBlast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.Early intranasal insulin therapy halts progression of neurodegeneration: progress in Alzheimer's disease therapeutics.The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepirideType 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4.Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model.Relationships between diabetes and cognitive impairmentExendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in miceDPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal CellsPotential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease.Glycation in Parkinson's disease and Alzheimer's disease.Ghrelin, Amylin, Gastric Inhibitory Peptide and Cognition in Middle-Aged HIV-Infected and Uninfected Women: The Women's Interagency HIV Study.Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury.Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis.Exendin-4 Enhances Motor Function Recovery via Promotion of Autophagy and Inhibition of Neuronal Apoptosis After Spinal Cord Injury in Rats.
P2860
Q26750746-79BE8B4E-20E5-45B4-86EF-5A187B22A4B1Q26866392-CCDEDE63-1862-47CE-8696-DBCE24AE2306Q27003253-667E54DE-C9AD-4037-BA14-68AB8D3942F9Q27021700-25B24444-42E1-4136-AFFE-455C164347D1Q28259585-AF9332F9-3096-4E97-A7EC-8611E092054EQ33896118-87106B5B-B89F-44BC-B0BF-EC424C6D7E51Q35226164-C04556D4-1D8B-4927-82AE-452E42E40F9EQ35768362-D373B359-64F4-4ACD-8D16-1290EC41A59FQ35853973-A761F753-F06F-4FE6-9C1C-EF01EC37E6E0Q35858095-DD649BC0-9281-493E-83EF-D376D6E749B1Q35960169-DCB1E94E-E123-44EE-B2E3-C5E61F6195E4Q35997824-5179547E-0F96-4D53-ABFA-B407F7C24D6BQ36471528-EF59463C-8E90-456B-B719-3FCB0D2F4538Q36551193-3FEF572D-AAED-4723-A048-0B4324A517E8Q36720655-F66EF785-7479-4038-945D-2C5D1E2ACA9AQ36905790-1AA5E41A-58A2-4EBE-AA22-F6D284EA4FB0Q36997912-C382CC64-42B9-40ED-BC31-34C2970132BAQ37162219-6648EEFC-C6D5-4C4D-9D5A-545F3FF8DE40Q37179909-8C123194-1636-4C3E-9258-CA9EA374D823Q37275631-1EB7AF24-E98C-42E6-84F7-352A0126ADE8Q38039489-DFBCA5AE-9E68-4180-A200-EAD97EEAD3BBQ38739185-186BC472-17C4-4635-9399-E2BE9450C8E8Q38762228-41C68A3B-798A-4BAB-BB6A-44981790E54FQ40129940-879131FE-C9C5-4490-9632-2D5A7FD39ADCQ42181887-4E2BC0C9-31D3-41A0-A1D0-5BDDD7547980Q46945027-228D2B2A-F6C0-45A6-A5E9-F6A52F94F81EQ48488584-446E8059-7793-4D64-9F7A-7077E7A26E93Q48940179-FB3E09E9-D79D-436B-BC6F-844F840669DAQ49015193-613282D0-12B6-4B60-9F0B-0C6F12DD0C15Q51021916-0443469D-DE5A-4346-8B3A-ACD4A78FC2B7Q53414688-A2707832-9D31-48F2-B717-3EF1215F66B0
P2860
Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incretin analogues that have b ...... ategy for Alzheimer's disease.
@en
Incretin analogues that have b ...... ategy for Alzheimer's disease.
@nl
type
label
Incretin analogues that have b ...... ategy for Alzheimer's disease.
@en
Incretin analogues that have b ...... ategy for Alzheimer's disease.
@nl
prefLabel
Incretin analogues that have b ...... ategy for Alzheimer's disease.
@en
Incretin analogues that have b ...... ategy for Alzheimer's disease.
@nl
P1476
Incretin analogues that have b ...... rategy for Alzheimer's disease
@en
P2093
Christian Holscher
P304
P356
10.2174/157488910791213130
P577
2010-06-01T00:00:00Z